Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
For breast cancer patients, BRCA gene mutations are predictive of a good response to chemotherapy, but are hampered by a high risk of bilateral and synchronous or metachronous ovarian cancer. Novel therapies such as PARP-inhibitors have proven effective for BRCA1/2 mutated ovarian cancer. We present the case of a 50-year-old woman, initially diagnosed with bilateral luminal B breast cancer with BRCA1 mutation. She received neoadjuvant chemotherapy, modified radical mastectomy and bilateral adnexectomy, while subsequently identifying a synchronous advanced ovarian cancer, stage FIGO IIIC, followed by adjuvant platinum chemotherapy and external radiotherapy. After a 12 months disease-free interval a brainstem tumor was discovered, for which whole-brain radiotherapy was performed. She received 6 months of PARP-inhibitors through an early access program. With only a partial at the end of treatment, the brainstem tumor was still in progression. Due to evolution of the brain metastasis, second line chemotherapy (taxanes and Bevacizumab) was administered, with complete radiologic response. The particularity of this case resides in the coexistence of a breast and ovarian cancer in the same patient with BRCA1-germline mutation who responded to a new line of therapy – the PARP inhibitors. While being unable to perform a biopsy, we speculate that the brain metastasis in this case was most likely of breast origin.
##plugins.themes.bootstrap3.article.details##
brain metastasis, BRCA mutation, breast cancer, ovarian cancer, PARP inhibitors
2. Dilawari A, Cangiarella J, Smith J, Huang A, Downey A, Muggia, F. Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. Ecancermedicalscience 2008; 2:109.
3. Szarszewska M, Markowska A, Jach R et al. Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis – A multicentre study. Adv Med Sci 2019; 64(2):235-240.
4. Asphaug L, Melberg HO. The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway. MDM Policy Pract 2019; 4(1):2381468318821103.
5. Li CM, Oren Y, Regev A, Brugge JS. Contribution of mutant microenvironment to hereditary cancer: Single-cell gene expression profiling of a genetically engineered mouse model of human hereditary BRCA1-related breast cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond; 2017 Sep 24-27; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018; 78(10 Suppl):Abstract nr PR06.
6. Manchana T, Lertkhachonsuk R, Teerapakpinyo C. Somatic BRCA mutation in high grade epithelial ovarian cancer patients. Asian Pac J Cancer Biol 2019, 3(4):99-103.
7. Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma. Cancer 2000; 88(12):2739–2750.
8. Verhoog IC, Brekelmans CTM, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351(9099):316-321.
9. Petrucelli N, Daly M B, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. SourceGeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. [https://www.ncbi.nlm.nih.gov/pubmed/20301425 available at 09.17.2019].
10. Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK. Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol Oncol 2019 153(3):568-573.
11. McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018; 7:212540. DOI: 10.7573/dic.212540.
12. Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL. BRCA1 mutations associated with increased risk of brain metastases in breast cancer: a 1:2 matched-pair analysis. Am J Clin Oncol 2018; 41(12):1252-1256.
13. Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737):235-244.
14. Hartman M, Czene K, Reilly M, et al. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 2005; 6(6):377–382.
15. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377:523-533.
16. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010; 122(1):1-7.
17. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. Screening and Diagnosis. Version 1.2019 [https://www2.tri-kobe.org/nccn/guideline/breast/english/breast-screening.pdf available at 09.18.2019]
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.